Microbleeds, Age Contribute to ARIA Risk With Aducanumab
Amyloid-related imaging abnormalities occurred in about 40% of participants in the phase 3 aducanumab studies ― and roughly one fourth of these experienced symptoms.
Stephen Salloway Martinm Zucker Madhav Thambisetty Drug Administration National Institute On Aging In Baltimore Butler Hospital
Source: medscape.com